http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002173630-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-93 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2001-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42e71cba639bc9054d44fd8fbbaf824a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ead46f364e66db3d999cd8a8b0c7e8da |
| publicationDate | 2002-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002173630-A1 |
| titleOfInvention | 33217, a novel human AMP-binding enzyme family member and uses thereof |
| abstract | The invention provides isolated nucleic acids molecules, designated 33217 nucleic acid molecules, which encode novel AMP-binding enzyme members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33217 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33217 gene has been introduced or disrupted. The invention still further provides isolated 33217 proteins, fusion proteins, antigenic peptides and anti-33217 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. |
| priorityDate | 2000-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1482.